Report Detail

Pharma & Healthcare Lupus Nephritis Global Clinical Trials Review, H2, 2019

  • RnM3864455
  • |
  • 10 January, 2020
  • |
  • Global
  • |
  • 173 Pages
  • |
  • GlobalData
  • |
  • Pharma & Healthcare

Lupus Nephritis Global Clinical Trials Review, H2, 2019

Summary

GlobalData's clinical trial report, “Lupus Nephritis Global Clinical Trials Review, H2, 2019" provides an overview of Lupus Nephritis clinical trials scenario. This report provides top line data relating to the clinical trials on Lupus Nephritis . Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Table of Contents

    List of Tables 4

      List of Figures 5

        Report Guidance 6

          GlobalData Clinical Trials Report Coverage 7

            Clinical Trials by Region 8

              Clinical Trials and Average Enrollment by Country 9

                Top Five Countries Contributing to Clinical Trials in Asia-Pacific 12

                  Top Five Countries Contributing to Clinical Trials in Europe 13

                    Top Countries Contributing to Clinical Trials in North America 14

                      Top Five Countries Contributing to Clinical Trials in Middle East and Africa 15

                        Top Five Countries Contributing to Clinical Trials in Central and South America 16

                          Clinical Trials by G7 Countries: Proportion of Lupus Nephritis to Immunology Clinical Trials 17

                            Clinical Trials by Phase in G7 Countries 18

                              Clinical Trials in G7 Countries by Trial Status 19

                                Clinical Trials by E7 Countries: Proportion of Lupus Nephritis to Immunology Clinical Trials 20

                                  Clinical Trials by Phase in E7 Countries 21

                                    Clinical Trials in E7 Countries by Trial Status 22

                                      Clinical Trials by Phase 24

                                        In Progress Trials by Phase 25

                                          Clinical Trials by Trial Status 26

                                            Clinical Trials by End Point Status 28

                                              Subjects Recruited Over a Period of Time 29

                                                Clinical Trials by Sponsor Type 30

                                                  Prominent Sponsors 31

                                                    Top Companies Participating in Lupus Nephritis Therapeutics Clinical Trials 33

                                                      Prominent Drugs 35

                                                        Latest Clinical Trials News on Lupus Nephritis 36

                                                          Nov 11, 2019: Genentech’s Gazyva (obinutuzumab), in Combination With Standard of Care, More Than Doubles the Percentage of Lupus Nephritis Patients Achieving Complete Renal Response, Compared To Standard of Care Alone 36

                                                            Nov 08, 2019: Apellis Presents First Data on APL-2 in C3 Glomerulopathy at ASN Kidney Week 36

                                                              Nov 06, 2019: Equillium to present new data and insights on the CD6-ALCAM pathway in Lupus Nephritis at ACR 2019 37

                                                                Oct 16, 2019: Aurinia reports last patient study visit in Aurora phase 3 lupus nephritis study and provides update on ATM facility 37

                                                                  Oct 11, 2019: Apellis to present data on APL-2 in complement 3 Glomerulopathy at ASN Kidney Week 2019 38

                                                                    Oct 01, 2019: Equillium Announces Initiation of the EQUALISE Phase 1b Clinical Trial of Itolizumab for Patients with Lupus Nephritis and Provides Business Update 38

                                                                      Sep 25, 2019: Omeros announces publication of study showing that inhibition of MASP-2, the key enzyme of the complement system’s Lectin Pathway, protects against renal injury caused by Proteinuria 39

                                                                        Sep 19, 2019: Roche receives FDA breakthrough status for lupus nephritis drug 39

                                                                          Clinical Trial Profile Snapshots 40

                                                                            Appendix 176

                                                                              Abbreviations 176

                                                                                Definitions 176

                                                                                  Research Methodology 177

                                                                                    Secondary Research 177

                                                                                      About GlobalData 178

                                                                                        Contact Us 178

                                                                                          Source 179

                                                                                          Summary:
                                                                                          Get latest Market Research Reports on Lupus Nephritis. Industry analysis & Market Report on Lupus Nephritis is a syndicated market report, published as Lupus Nephritis Global Clinical Trials Review, H2, 2019. It is complete Research Study and Industry Analysis of Lupus Nephritis market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

                                                                                          Last updated on

                                                                                          REPORT YOU MIGHT BE INTERESTED

                                                                                          Purchase this Report

                                                                                          $2,500.00
                                                                                          $5,000.00
                                                                                          $7,500.00
                                                                                          1,972.50
                                                                                          3,945.00
                                                                                          5,917.50
                                                                                          2,335.00
                                                                                          4,670.00
                                                                                          7,005.00
                                                                                          393,700.00
                                                                                          787,400.00
                                                                                          1,181,100.00
                                                                                          208,950.00
                                                                                          417,900.00
                                                                                          626,850.00
                                                                                          Credit card Logo

                                                                                          Related Reports


                                                                                          Reason to Buy

                                                                                          Request for Sample of this report